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ABSTRACT
In conjunction with a randomized trial of T-cell depletion versus conventional graft-versus-host disease
(GVHD) prophylaxis, we assessed GVHD grading by comparing the transplant center 100-day score, a
clinically calculated algorithm, and a blinded expert panel review (PR). Weekly skin, gut, and liver clinical
staging; clinically verified differential diagnosis; biopsy information; cyclosporine levels; and initiation of
treatment were reviewed and graded according to the consensus GVHD grading method modified by a
prospectively determined grading algorithm that specified liver and gut downstaging if a differential diagnosis
in that organ was identified. Transplant center (TC) determination of maximum grade was compared with the
algorithm-calculated grade and the final expert PR. Of 404 patients reviewed, the TC grade concurred with the
calculated algorithm grade in 72% (the algorithm upgraded 18% and downgraded 10%), whereas the TC grade
agreed with the PR in 77% (the PR upgraded 12% and downgraded 11%). The calculated algorithm grade was
nearly fully (92%) concordant with the final PR grade (the PR upgraded 0.7% and downgraded 7%). Blinded,
duplicate reviews for quality control (n  108) agreed with the initial review in 89% of cases. Algorithm and/or
PR review reduced the TC-reported incidence of grade II (28% to 23%) and increased grade III (11% to 20%),
whereas grade 0 (41% to 42%), grade I (13% to 12%), and grade IV (7% to 6%) were invariant. Recalculation
of the algorithm grading without differential diagnosis downstaging reduced agreement with the TC to a small
extent. The original algorithm changed 51 (13%) of 404 from grade 0 to II into grade III or IV or vice versa;
calculation without the downgrade modified 44 cases (11%). Maximum acute GVHD grade had a major effect
on 2-year disease-free survival, but assignment by TC, calculated algorithm, or final PR grade had little effect
on survival within grades or grade categories 0 through II versus III or IV. We conclude that detailed and
expert PR yields GVHD scoring that is internally consistent and reproducible with 89% concordance. Weekly
recording of GVHD stage along with a calculated grading algorithm acknowledging differential diagnoses
results in a final and maximum grade nearly fully concordant with the expert blinded PR. Multicenter
prospective GVHD scoring using all available weekly staging and differential diagnosis data can be reliably
assessed with a clinically relevant algorithm. This approach can thereby reduce investigator bias, facilitate
comparison between centers, and perhaps eliminate the need for an expert PR. This technique should be used
in future prospective studies of GVHD prophylaxis.
© 2003 American Society for Blood and Marrow Transplantation
KEY WORDS
Graft-versus-host disease ● Bone marrow transplantation ● Grading ● Biopsy
Biology of Blood and Marrow Transplantation 9:512-518 (2003)
 2003 American Society for Blood and Marrow Transplantation
1083-8791/03/0908-0005$30.00/0
doi:10.1016/S1083-8791(03)00162-9
512
INTRODUCTION
Graft-versus-host disease (GVHD) remains the
most frequent serious complication after allogeneic
hematopoietic stem cell transplantation [1-3]. Its clin-
ical manifestations of rash, nausea, vomiting, and di-
arrhea or cholestasis are complicated by ongoing im-
munocompromise and additional risk of infection.
However, these multiorgan manifestations resemble
other skin rashes, gut disturbances, or hepatic abnor-
malities that frequently accompany allogeneic trans-
plantation [4,5]. Although several clinical grading
schemes have been published [6-8] and histologic cri-
teria for the diagnosis have been established [9-17],
uniform applicability and reproducibility of acute
GVHD clinical grading has been questioned [18,19].
In conjunction with a prospective, randomized trial of
GVHD prophylaxis comparing ex vivo T-cell deple-
tion (TCD) with in vivo immunosuppressive therapy,
we prospectively evaluated the utility of a deﬁned
clinical grading algorithm and contrasted its repro-
ducibility and validity with that of a blinded expert
panel review (PR) to determine the clinical GVHD
grade for each participant in this trial. The formal
assessment of these grading schemes is reported.
METHODS
In 1995, a multicenter prospective trial testing ex
vivo TCD versus conventional posttransplantation
immunosuppressive therapy was initiated supported
by funding from the National Heart, Lung, and Blood
Institute. At 15 participating centers, 410 patients
were enrolled to evaluate 2 different methods for
TCD of donor bone marrow in comparison to meth-
otrexate plus cyclosporine as GVHD prophylaxis on
3-year disease-free survival (DFS). Of the 410 pa-
tients, 404 were evaluable for acute GVHD; 5 patients
died before undergoing transplantation, and 1 under-
went transplantation 2 years after enrollment (no
acute GVHD information was available). Patients re-
ceived cyclophosphamide with or without cytarabine
(with T10B9 TCD) and total body irradiation and
either methotrexate plus cyclosporine or ex vivo TCD
by using either counterﬂow elutriation [20] with a
deﬁned CD3 T-cell dose or antibody plus comple-
ment TCD by using the murine monoclonal antibody
T10B9 [21]. Details of supportive care, including an-
tibiotics, transfusions, and pharmacologic drug man-
agement, were standardized according to the multi-
center trial guidelines.
GVHD staging in skin, gut, and liver was prospec-
tively recorded by using the consensus GVHD staging
and grading criteria [7], and 4751 individual patient
weekly GVHD reports as diagnosed by the transplant
center (TC) investigators were received. Weekly
GVHD maximum staging was based on the extent of
skin rash, volume of diarrhea, presence of nausea or
vomiting, or increased serum bilirubin. Results of
skin, gut, or liver biopsies, if performed, were available
for review, along with weekly trough blood levels of
cyclosporine. In addition, investigators at each TC
indicated whether additional differential diagnoses
potentially contributed to the observed pathology in
the skin, gut, and liver. Differential diagnoses were
suggested (as checkbox options) but were not limited
to the following—skin: drug rash, infection, and reg-
imen toxicity; gut: infection, regimen toxicity, and
drug toxicity; and liver: veno-occlusive disease, total
parenteral nutrition, and drug toxicity.
The pretrial-speciﬁed grading algorithm calcu-
lated the weekly GVHD clinical grade on the basis of
the recorded weekly organ staging in skin, gut (upper
or lower), and liver. However, if a listed speciﬁc dif-
ferential diagnosis was offered for either gut or liver,
the calculated organ stage was downstaged by 1, and
the clinical grade was calculated by the algorithm
accordingly. For example, a bilirubin level of 8 mg/dL
in conjunction with a listed differential diagnosis of
veno-occlusive disease would be assessed for grading
purposes as liver GVHD, stage 3, downstaged and
calculated as liver stage 2. With this differential diag-
nosis–adjusted grading algorithm, weekly GVHD
maximum grades were calculated for the algorithm
according to the GVHD consensus grading scheme as
described [7]. In the consensus GVHD grading
scheme, grade I includes skin stage 1 or 2, gut stage 0,
and liver stage 0; grade II includes skin stage 0 to 3,
gut stage 0 or 1 (or upper gastrointestinal tract), or
liver stage 0 or 1; grade III includes skin stage 0 to 3,
gut stage 0 to 4, and liver stage 0 to 3; and grade IV
includes any involvement with skin stage 4 or lesser
gut or other organ stage along with an extreme de-
crease in performance status.
For the expert PR, experienced transplant clini-
cians (D.J.W., D.H., C.H., N.A.K.) and study coor-
dinating center personnel (S.C.) were each presented
tables displaying each patient’s weekly GVHD staging
in skin, gut, and liver; this was recorded along with
biopsy results (positive, negative, or not done), speci-
ﬁed differential diagnoses, trough cyclosporine levels,
initiation of systemic anti-GVHD therapy, and calcu-
lated weekly clinical algorithm grade adjusted for dif-
ferential diagnoses. These multiple-week tables, with-
out patient demographic information or knowledge of
the randomized GVHD prophylaxis technique used,
were independently reviewed in comparison to the
GVHD scoring algorithm–calculated maximum clin-
ical grade of acute GVHD and the TC-reported max-
imum acute GVHD grade indicated on the day 100
data form reported to the National Marrow Donor
Program, which requests the maximum organ stage
and grade of acute GVHD before day 100.
The panel members independently reviewed each
Grading of Acute GVHD
513BB&MT
patient’s GVHD record, and each voted to agree with
the TCD algorithm, disagree, or ask for additional
data. Subsequently, in conference, each patient’s
GVHD record was discussed, and the panel’s areas of
disagreement were resolved. The panel’s ﬁnal review
grade was adjusted after clinical interpretation of con-
ﬂicting data, circumstances that suggested data error,
or other information supplied through data queries to
the TC. Supplemental data queries included clariﬁca-
tion of differential diagnoses, veriﬁcation that sys-
temic anti-GVHD therapy was initiated in a given
week, or clariﬁcation of reported biopsy results, if any.
No unblinded or raw data were presented to the ex-
pert panel during their review.
Descriptive statistics compared the expert PR with
the computed algorithm and with the TC grade sub-
mitted to the National Marrow Donor Program. The
frequency of discrepancy among the 3 grading tech-
niques was evaluated by overall grade and by organ-
speciﬁc stage for the whole group and within TCD
and conventional immunoprophylaxis subgroups.
Agreement frequencies were compared by using a
repeated-measures model with a logit link.
Product-limit estimates of survival distributions
were constructed for the DFS end point. The predic-
tive value of the algorithm acute GVHD grade was
assessed by using the current maximum acute GVHD
as a time-varying covariate in a Cox proportional
hazards model [22-24] that included patient and donor
age, diagnosis, depletion strategy, GVHD prophylac-
tic technique, disease stage, HLA match, and recipient
cytomegalovirus serostatus as potential covariates.
The tissue biopsies performed to establish or con-
ﬁrm a clinical diagnosis of GVHD were assessed in
comparison to the patients’ overall diagnoses of
GVHD. Each biopsy’s predictive value (positive [true
positive/true positive  false positive] or negative
[true negative/false negative  true negative]), sensi-
tivity (true positive/true positive false negative), and
speciﬁcity (true negative/false positive  true nega-
tive) were calculated in the context of the overall
clinical and/or pathologic diagnosis of GVHD for
each patient. For these evaluations, the clinical diag-
nosis of GVHD was determined by the TC, with ﬁnal
stage/grade calculated by the algorithm.
RESULTS
Patients
The patients’ clinical characteristics are detailed in
Table 1. As shown, 404 patients (201 receiving TCD
and 203 receiving conventional GVHD immunopro-
phylaxis) were studied. The 2 groups were balanced by
age, diagnosis, disease stage, donor age, cytomegalo-
virus serostatus, and pretransplantation Karnofsky
score.
Most patients were adults and white. Consistent
with the trial design, roughly half of all patients had
acute leukemia, and half had chronic myelogenous
leukemia. Seventy-ﬁve percent of patients had good
risk status (chronic myelogenous leukemia in the ﬁrst
chronic phase or acute leukemia in ﬁrst or second
complete remission), and approximately 70% of pa-
tients had matched unrelated donors deﬁned by low-
resolution serologic matching at HLA A and B and
DNA-based, allele-level matching at HLA-DRB1.
Acute GVHD Grading
The maximum grade of acute GVHD is shown in
Table 2. Approximately 40% of patients had no signs
of GVHD with all 3 scoring methods, and 12% to
13% had limited cutaneous GVHD (maximum grade
I). The TCs reported 28% grade II GVHD, but both
the differential diagnosis–acknowledging algorithm
and the ﬁnal PR identiﬁed only 23% grade II acute
GVHD. The TC grades also showed less frequent
grade III than either the algorithm or the PR grades.
Only a small minority, 6% to 7%, had grade IV
GVHD with each method. The grade changes used in
each technique showed that 10% of patients reported
as grade 0 to II by the TC were upgraded to grade III
Table 1. Patient Characteristics
Variable
GVHD Prophylaxis
T-Cell
Depletion Conventional
n 201 203
Age (y), median (range) 31.3 (0.5-55.6) 30.6 (0.6-54.0)
Male (%) 55 53
Ethnicity (%)
White 83 85
Hispanic 6 4
Black 8 8
Other 3 3
Diagnosis (%)
Acute leukemia 45 47
Chronic myelogenous
leukemia 46 43
Myelodysplastic
syndrome 6 6
Other 3 3
Good-risk group (%) 72 74
Donor age, y, median
(range) 36 (19-59)* 35 (21-55)
HLA match (%)
6 of 6 antigen match 72 73
5 of 6 antigen match 28 27
Cytomegalovirus
serostatus (%)
Recipient positive 47 41
Donor positive 35 35
Karnofsky status (%)
100 39 31
80-90 55 66
*n  199.
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or IV by the algorithm. The converse was uncommon;
only 2% of TC patients were downgraded from grade
III or IV down to 0 through II GVHD by algorithm
grading. Similarly, algorithm to PR changes were un-
common. There was very little change between algo-
rithm and PR grading (n 31), whereas the frequency
of changes between TC and algorithm grades was
much greater (n  115; P  .001). Overall, 18% of
patients were upgraded with the algorithm, but very
rarely did the algorithm versus PR increase patients’
GVHD grades. Downgrading was less frequent, with
10% of patients downgraded by the algorithm, but an
additional 7% were downgraded by PR. This suggests
that the TC, in grading patients without explicit ac-
knowledgment of any differential diagnoses, still un-
derscored acute GVHD compared with the clinical
algorithm. In addition, the clinical algorithm was
highly concordant with the blinded expert PR. Ac-
knowledging the relevant differential diagnoses and
accommodating all apparent target organ symptoms
may allow the algorithm to grade GVHD more con-
sistently than the individual TC reports.
GVHD Grading and DFS
These 3 grading schemes all showed that the de-
velopment of acute GVHD has a signiﬁcant effect on
2-year DFS. As shown in Figure 1, approximately one
third of the patients with no acute GVHD were alive
without leukemia at 2 years after transplantation. Each
grading method showed approximately the same frac-
tion of patients having no GVHD and showed similar
DFS. Patients with grade I GVHD were identiﬁed
with similar frequency by using all 3 grading methods.
These patients had nearly twice as good DFS as those
with grade II or III GVHD. The TC grading showed
less frequent grade III GVHD and equivalent DFS in
groups with maximum grade II or grade III GVHD.
In contrast, the algorithm grading scheme yielded a
2-year DFS of 9% better with grade II versus III, and
the PR scoring method yielded a DFS of 14% better
in grade II versus grade III. Patients with grade IV
GVHD were consistently identiﬁed by all 3 methods
and had poor DFS. These results did not differ be-
tween the conventional and TCD strategies (results
not shown).
However, assigning GVHD ﬁnal grades and ana-
lyzing survival fails to address the time course of
GVHD onset. Accordingly, we analyzed DFS by us-
ing the algorithm grade in a regression model, con-
sidering the current highest GVHD grade as a time-
varying covariate. Compared with maximum grade 0
with a relative hazard (RH) of 1.0, grade I GVHD led
to an RH of 0.69 (95% conﬁdence interval, 0.44-1.09;
P .11); grade II led to an RH of 1.07 (0.77-1.50; P
0.68); grade III led to an RH of 1.49 (1.06-2.11; P 
.02); and grade IV led to an RH of 6.38 (3.95-10.31;
P  .001). This model documents progressively
higher risks for poor DFS in patients with grade II,
III, or IV GVHD. Compared with grade II, those with
grade III had a relative risk of 1.39 (P  .07), and
grade IV versus III had a relative risk of 4.28 (P 
.001). With the algorithm grading scheme, progres-
sively poorer outcome was also seen with each higher
grade of GVHD (II, III, and IV). These data strongly
suggest that the lower GVHD scores reported from
TC incorporate less prognostic information for DFS
Figure 1. Effect of GVHD grade and grading method on 2-year
disease-free survival. Shown are the Kaplan-Meier 2-year disease-
free survival percentages for patients with each GVHD grade de-
termined by the 3 scoring methods. ALG indicates algorithm.
Table 2. Maximum Acute GVHD Grade: Comparison of 3 Scoring
Methods
Variable
Panel
Review (PR)
Algorithm
(ALG)
Transplant
Center (TC)
Maximum grade (%)*
0 42 38 41
I 13 12 13
II 23 23 28
III 16 20 11
IV 6 7 7
Grade changes, n (%)† TC to ALG ALG to PR
0-II to III/IV 42 (10%) 1 (0.2%)
III/IV to 0-II 9 (2%) 17 (4%)
Grade increase 73 (18%) 3 (0.7%)
Grade decrease 42 (10%) 28 (7%)
*Shown are the maximum GVHD clinical grades for all patients
scored by each method. TC reported more patients with grade II
and fewer with grade III GVHD than the ALG or PR grading
methods.
†The numbers (%) of patients with GVHD grade changes with
the different grading methods are shown. Changes were most fre-
quent between the TC and ALG methods, whereas concordance
was greater with ALG or PR.
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and imprecisely classify patients with more severe
GVHD within grade II (instead of grade III) who will
experience worse DFS.
Histologic Confirmation of GVHD
Approximately 60% of patients had tissue biopsies
to validate the clinical diagnosis of GVHD. As shown
in Figure 2, 194 patients had 263 skin biopsies, and
most were positive. Eighty-seven skin biopsies were
negative, with a negative predictive value of 40.2%,
whereas a positive or equivocal biopsy (n  176) had
a positive predictive value of 97.7%. Skin biopsies,
therefore, had a sensitivity of 76.8% and a speciﬁcity
of 89.7%. One hundred forty-eight patients had 214
gastrointestinal tract biopsies, and 100 were positive
or equivocal. A negative gut biopsy had a negative
predictive value of 28.1%, and a positive or equivocal
biopsy had a positive predictive value of 100%. Gut
biopsy sensitivity was 54.9%, and speciﬁcity was
100%. Only 15 patients had liver biopsies, and 10
showed no histologic evidence of GVHD. A negative
biopsy had a negative predictive value of 30%, and a
positive or equivocal biopsy had a positive predictive
value of 100%. Liver biopsy sensitivity was 41.7%,
and speciﬁcity was 100%.
PR Quality Control
Of 404 patients’ GVHD records, 108 (27%) were
rereviewed by the blinded panel to assess the consis-
tency and reproducibility of the expert PR in grading
GVHD. Eighty-nine percent of PR yielded reproduc-
ible GVHD grades. Only 12 (11%) of the validating
repeat PR modiﬁed the original PR grade, and only 8
(7%) changed the grade classiﬁcation between grades
0 through II and grade III or IV GVHD. Rereview
upgraded 4 patients from grades 0 to II to grade III or
IV and downgraded 4. Seven patients had increased
and 5 had decreased GVHD ﬁnal grades on rereview.
DISCUSSION
The clinical grading of acute GVHD has had little
modiﬁcation in the 29 years since the original grading
scheme was published. The original Glucksberg re-
port classiﬁed 43 of 61 patients with GVHD [6]. Two
formal modiﬁcations of GVHD grading schemes have
been reported since. A consensus panel in 1995 ac-
knowledged the importance of acute GVHD involv-
ing the upper gastrointestinal tract as a manifestation
of systemic GVHD requiring classiﬁcation as grade II
or higher [7,25]. In 1997, investigators from the In-
ternational Bone Marrow Transplant Registry pro-
posed an alternate reassignment of conventional
GVHD organ staging into clinical grades A, B, C, and
D instead of I, II, III, and IV [8]. This classiﬁcation
reportedly distinguished survival more effectively than
either the original or the consensus-modiﬁed grading
schemata, primarily because of the breadth of GVHD
severity incorporated in clinical grade II GVHD [19].
Because GVHD develops over time, premature
death from other causes may limit the maximum grade
of GVHD achieved. Simple classiﬁcation of ﬁnal
GVHD grading to test its effect on survival fails to
account for other competing hazards and early deaths
not directly attributable to the advanced GVHD
grades. Therefore, we tested the development of each
GVHD grade as a time-varying covariate in a multi-
variate regression model and showed progressively
poor DFS by using the algorithm grade for each step
beyond grade II. This analysis, which treated GVHD
as a time-varying covariate, better reﬂects the kinetic
nature of GVHD onset and the critical competing
hazards involved in evaluating its effect on survival.
The relationship in assignment of GVHD grading
and effect on outcome was also recognized in our
analysis of GVHD grading within the more homoge-
neous context of a prospective clinical trial. TC as-
signment of clinical grade underscored a sizable frac-
tion of patients, primarily by discounting organ
involvement, which the clinical algorithm incorpo-
rated by using the algorithm-designated downstaging
rules. Differential diagnosis of organs involved with
GVHD has always been problematic in GVHD stag-
ing and has been poorly accommodated by previously
published grading schemata. Some reports suggest
discounting any GVHD target organ involvement
when such comorbidity is recognized because it con-
founds assessment of the effect of GVHD therapy [2].
However, this approach may again underestimate the
clinical burden of GVHD because, for example, the
presence of an intestinal infection does not protect
patients from gut GVHD, nor does drug-induced
liver dysfunction protect patients from hepatic
GVHD. The current clinical algorithm acknowledges
the potential of these differential diagnoses to alter the
clinical manifestations of organ injury, but it also rec-
Figure 2. Histologic conﬁrmation of GVHD grade: percentage
distribution of skin, gastrointestinal, and liver biopsy results for
panel review acute GVHD grades. Shown are the percentage (and
number) of positive, equivocal, or negative biopsies for organ in-
volvement with GVHD in patients with differing clinical GVHD
grade (by panel review). Most skin biopsies—152 (58%) of 263—
were positive in patients with GVHD, whereas 91 (43%) of 214 gut
and 5 (33%) of 15 liver biopsies were positive in GVHD patients.
D. J. Weisdorf et al.
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ognizes the comorbidity of other diagnoses in overall
clinical GVHD grading by downstaging gut and liver
organ involvement. This clinical algorithm accommo-
dates the morbidity of GVHD, particularly grade III,
better than the TC estimate of GVHD involvement
[7]. It is validated by the observation of poorer DFS in
patients with grade III versus grade II GVHD scored
by either the algorithm or PR compared with the TC
approach. This strongly suggests that TC grading
homogenizes the biologic distinction between grades
II and III, whereas the clinical algorithm, validated by
the PR assessment, can better distinguish patients
with more severe GVHD leading to poorer DFS.
The reproducibility of GVHD scoring has long
been questioned. Only modest reproducibility was re-
ported in a questionnaire survey in the late 1980s [18],
and similar disparities were recognized in a recent
analysis of chronic GHVD multicenter scoring [26].
In our report, formal and blinded rereview yielded
concordance in GVHD grading in 89% of cases and
reproducible classiﬁcation of GVHD grade 0 to II
versus grade III or IV in 93% of cases.
Prospective single or multicenter trials testing
GVHD prophylactic techniques [27,28] or GVHD
treatment are limited by the difﬁculties in scoring
acute GVHD in a reproducible and valid fashion. The
clinical algorithm reported herein requires each pa-
tient’s organ staging to be reported on a weekly basis
along with relevant differential diagnoses—these data
are generally requested in all trials that formally assess
acute GVHD. The calculated clinical algorithm pro-
duces reliable and reproducible recognition of differ-
ent GVHD severities and accommodates the comor-
bidities of additional toxicities in the GVHD target
organs. It is important to note that the validity of the
algorithm (or the expert PR) is limited by any bias in
TC reports of relevant differential diagnoses. This
limitation is inherent in any multicenter assessment of
GVHD severity. However, because the algorithm
nearly completely reproduces the blinded expert PR,
this clinical algorithm might substitute for the time-
consuming and burdensome effort of a grading panel,
yet still yield reproducible and valid GVHD grading.
We suggest that multicenter prospective GVHD scor-
ing use all available weekly staging data, as well as
information regarding differential diagnoses. GVHD
can be reliably assessed with a clinically relevant algo-
rithm, thus increasing the comparability of GVHD
grading between centers, reducing investigator bias,
and possibly eliminating the need for expert PR. This
validated technique should be applied for staging and
grading in future trials of GVHD prevention.
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